Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2012

01-03-2012 | Original article

SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells

Authors: Jing-Jing Wei, Chuan-Wang Song, Ling-Cong Sun, Ye Yuan, Dong Li, Bin Yan, Sheng-Jun Liao, Jian-Hua Zhu, Qi Wang, Gui-Mei Zhang, Zuo-Hua Feng

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Login to get access

Abstract

Mast cells may have either antitumor or tumor-promoting potential. Nevertheless, mast cells in tumor microenvironment have been found to promote tumor growth. So far the mechanisms underlying the modulation of mast cell function in tumor microenvironment remains to be fully elucidated. Here, we report that tumor-promoting potential of mast cells could be augmented by molecules released from damaged tumor cells through cooperative stimulation of stem cell factor (SCF) and ligand for Toll-like receptor 4 (TLR4). Co-simulation with SCF and TLR4 ligand inhibited mast cell degranulation, but efficiently induced the production and secretion of VEGF, PDGF, and IL-10. Although TLR4 ligand alone may induce IL-12 expression in mast cells, co-stimulation with SCF and TLR4 ligand induced the expression of IL-10, but not IL-12, in mast cells. The phosphorylation of GSK3β was crucial for the effect of SCF and TLR4 ligand. In addition to inducing phosphorylation of GSK3β at Ser9 through PI3K pathway, SCF and TLR4 ligand cooperated to induce phosphorylation of GSK3β at Tyr216 by simultaneous activation of ERK and p38MAPK pathways. Both phospho-Ser9 and phospho-Tyr216 of GSK3β were required for IL-10 expression induced by SCF/TLR4 ligand, whereas suppressive effect of SCF/TLR4 ligand on mast cell degranulation was related to phospho-Tyr216. Importantly, the effect of SCF and TLR4 ligand on mast cells could be abrogated by inhibiting phosphorylation of GSK3β at Tyr216. These findings disclose the mechanisms underlying the modulation of mast cell function in tumor microenvironment, and suggest that inhibiting GSK3β in mast cells will be beneficial to the treatment of cancer.
Literature
1.
go back to reference Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S et al (2007) Role of mast cells in tumor growth. Ann Clin Lab Sci 37:315–322PubMed Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S et al (2007) Role of mast cells in tumor growth. Ann Clin Lab Sci 37:315–322PubMed
2.
go back to reference Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796:19–26PubMed Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796:19–26PubMed
3.
go back to reference Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM (2008) A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 29:880–886PubMedCrossRef Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM (2008) A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 29:880–886PubMedCrossRef
4.
go back to reference Henderson WR, Chi EY, Jong EC, Klebanoff SJ (1981) Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system. J Exp Med 153:520–533PubMedCrossRef Henderson WR, Chi EY, Jong EC, Klebanoff SJ (1981) Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system. J Exp Med 153:520–533PubMedCrossRef
5.
go back to reference Kormelink TG, Abudukelimu A, Redegeld FA (2009) Mast cells as target in cancer therapy. Curr Pharm Des 15:1868–1878CrossRef Kormelink TG, Abudukelimu A, Redegeld FA (2009) Mast cells as target in cancer therapy. Curr Pharm Des 15:1868–1878CrossRef
6.
go back to reference Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211–1218PubMedCrossRef Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211–1218PubMedCrossRef
7.
go back to reference Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P (2003) Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 33:420–425PubMedCrossRef Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P (2003) Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 33:420–425PubMedCrossRef
8.
go back to reference Ribatti D, Crivellato E (2009) The controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol 275:89–131PubMedCrossRef Ribatti D, Crivellato E (2009) The controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol 275:89–131PubMedCrossRef
9.
go back to reference Ullrich SE, Nghiem DX, Khaskina P (2007) Suppression of an established immune response by UVA—a critical role for mast cells. Photochem Photobiol 83:1095–1100PubMedCrossRef Ullrich SE, Nghiem DX, Khaskina P (2007) Suppression of an established immune response by UVA—a critical role for mast cells. Photochem Photobiol 83:1095–1100PubMedCrossRef
10.
go back to reference Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8:1095–1104PubMedCrossRef Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8:1095–1104PubMedCrossRef
11.
go back to reference Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K et al (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997–1002PubMedCrossRef Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K et al (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997–1002PubMedCrossRef
12.
go back to reference Nakano N, Nishiyama C, Kanada S, Niwa Y, Shimokawa N, Ushio H, Nishiyama M, Okumura K, Ogawa H (2007) Involvement of mast cells in IL-12/23 p40 production is essential for survival from polymicrobial infections. Blood 109:4846–4855PubMedCrossRef Nakano N, Nishiyama C, Kanada S, Niwa Y, Shimokawa N, Ushio H, Nishiyama M, Okumura K, Ogawa H (2007) Involvement of mast cells in IL-12/23 p40 production is essential for survival from polymicrobial infections. Blood 109:4846–4855PubMedCrossRef
13.
go back to reference Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112:1269–1279PubMedCrossRef Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112:1269–1279PubMedCrossRef
14.
go back to reference Liu YY, Sun LC, Wei JJ, Li D, Yuan Y, Yan B et al (2010) Tumor cell-Released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J Immunol 185:2773–2782PubMedCrossRef Liu YY, Sun LC, Wei JJ, Li D, Yuan Y, Yan B et al (2010) Tumor cell-Released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J Immunol 185:2773–2782PubMedCrossRef
15.
go back to reference Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431:1007–1011PubMedCrossRef Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431:1007–1011PubMedCrossRef
16.
go back to reference Geng H, Zhang GM, Xiao H, Yuan Y, Li D, Zhang H, Qiu H, He YF, Feng ZH (2006) HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 118:2657–2664PubMedCrossRef Geng H, Zhang GM, Xiao H, Yuan Y, Li D, Zhang H, Qiu H, He YF, Feng ZH (2006) HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 118:2657–2664PubMedCrossRef
17.
go back to reference Walsh SK, Kane KA, Wainwright CL (2009) Mast cell degranulation—a mechanism for the anti-arrhythmic effect of endothelin-1? Br J Pharmacol 157:716–723PubMedCrossRef Walsh SK, Kane KA, Wainwright CL (2009) Mast cell degranulation—a mechanism for the anti-arrhythmic effect of endothelin-1? Br J Pharmacol 157:716–723PubMedCrossRef
18.
19.
go back to reference Qiao H, Andrade MV, Lisboa FA, Morgan K, Beaven MA (2006) FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 107:610–618PubMedCrossRef Qiao H, Andrade MV, Lisboa FA, Morgan K, Beaven MA (2006) FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 107:610–618PubMedCrossRef
20.
go back to reference Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH (2005) Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 175:3339–3346PubMed Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH (2005) Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 175:3339–3346PubMed
21.
go back to reference Theoharides TC, Conti P (2004) Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25:235–241PubMedCrossRef Theoharides TC, Conti P (2004) Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25:235–241PubMedCrossRef
22.
go back to reference Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217:65–78PubMedCrossRef Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217:65–78PubMedCrossRef
23.
go back to reference Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777–784PubMedCrossRef Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777–784PubMedCrossRef
24.
go back to reference Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling. Prog Neurobiol 65:391–426PubMedCrossRef Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling. Prog Neurobiol 65:391–426PubMedCrossRef
25.
go back to reference Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J, Minamoto T (2009) Potential therapeutic effect of glycogen synthase kinase 3 beta inhibition against human glioblastoma. Clin Cancer Res 15:887–897PubMedCrossRef Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J, Minamoto T (2009) Potential therapeutic effect of glycogen synthase kinase 3 beta inhibition against human glioblastoma. Clin Cancer Res 15:887–897PubMedCrossRef
26.
go back to reference Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ (2003) Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 4:974–981PubMedCrossRef Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ (2003) Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 4:974–981PubMedCrossRef
27.
go back to reference Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105–3113PubMedCrossRef Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105–3113PubMedCrossRef
28.
go back to reference Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H, Sato M, Okada Y, Takeyama H, Manabe T (2007) Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci 52:2292–2300PubMedCrossRef Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H, Sato M, Okada Y, Takeyama H, Manabe T (2007) Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci 52:2292–2300PubMedCrossRef
29.
go back to reference Metcalfe DD, Peavy RD, Gilfillan AM (2009) Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 124:639–646PubMedCrossRef Metcalfe DD, Peavy RD, Gilfillan AM (2009) Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 124:639–646PubMedCrossRef
30.
go back to reference Kim MS, Rådinger M, Gilfillan AM (2008) The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 29:493–501PubMedCrossRef Kim MS, Rådinger M, Gilfillan AM (2008) The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 29:493–501PubMedCrossRef
31.
go back to reference Kalesnikoff J, Rios EJ, Chen CC, Nakae S, Zabel BA, Butcher EC, Tsai M, Tam SY, Galli SJ (2006) RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proc Natl Acad Sci USA 103:2659–2664PubMedCrossRef Kalesnikoff J, Rios EJ, Chen CC, Nakae S, Zabel BA, Butcher EC, Tsai M, Tam SY, Galli SJ (2006) RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proc Natl Acad Sci USA 103:2659–2664PubMedCrossRef
32.
go back to reference Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166:3837–3845PubMed Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166:3837–3845PubMed
33.
go back to reference Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039–1046PubMed Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039–1046PubMed
34.
go back to reference Lawrence T (2007) Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci 28:162–165PubMedCrossRef Lawrence T (2007) Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci 28:162–165PubMedCrossRef
36.
go back to reference Lin WW, Karin MA (2007) Cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183PubMedCrossRef Lin WW, Karin MA (2007) Cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183PubMedCrossRef
37.
go back to reference Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014PubMedCrossRef Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014PubMedCrossRef
38.
go back to reference Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang GM, Feng ZH (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86–92PubMedCrossRef Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang GM, Feng ZH (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86–92PubMedCrossRef
39.
go back to reference Shin HY, Kim JS, An NH, Park RK, Kim HM (2004) Effect of disodium cromoglycate on mast cell-mediated immediate-type allergic reactions. Life Sci 74:2877–2887PubMedCrossRef Shin HY, Kim JS, An NH, Park RK, Kim HM (2004) Effect of disodium cromoglycate on mast cell-mediated immediate-type allergic reactions. Life Sci 74:2877–2887PubMedCrossRef
Metadata
Title
SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells
Authors
Jing-Jing Wei
Chuan-Wang Song
Ling-Cong Sun
Ye Yuan
Dong Li
Bin Yan
Sheng-Jun Liao
Jian-Hua Zhu
Qi Wang
Gui-Mei Zhang
Zuo-Hua Feng
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1098-z

Other articles of this Issue 3/2012

Cancer Immunology, Immunotherapy 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine